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Abstract 
Severe combined immunodeficiency (SCID) is an important health problem and is 
the most severe form of primary immunodeficiency. This syndrome is caused by genetic 
mutations that block the development of T cells. As such, serious T cell dysfunction 
precludes effective humoral immunity, as the B cells require signalization from T cells to 
generate antibodies. Based on the records from a combined prospective data analysis 
from the neonatal screening program in the United States of America, the incidence of 
SCID is approximately 1 in 58.000 infants. The early diagnosis of SCID before any clinical 
symptom or the occurrence of serious complications is proven to improve the survival 
rates after the hematopoietic stem cell transplantation, which is the recommended 
treatment. 
This literature review aims at analysing all the advantages and disadvantages of 
the implementation of SCID testing in all the neonatal screening programs.  
The search engine used to conduct this review was PubMed. 
In this paper, the presentation of SCID, the available screening methods to detect 
the disease and the cost-effectiveness related to the screening are presented in order to 
clarify all the components that need to be taken in consideration when adding a disease to 
a neonatal screening program. 
To conclude, the screening method for SCID that quantifies the T-cell receptor 
excision circles using reverse transcription for real-time quantitative polymerase chain 
reaction is proven to be cost-effective has a sensitivity and specificity of nearly 100% and 
allows to detect the disease at an early stage, while it still has a good prognosis. This 
method has already been implemented in some countries with good results. 
 
Key-words: Severe Combined Immunodeficiency; Neonatal Screening; Receptors, 
Antigen, T-Cell; Lymphopenia. 
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Resumo 
Imunodeficiência Combinada Grave (SCID) é um importante problema de saúde 
pública e a forma mais grave de imunodeficiência primária. Este síndrome é causado por 
mutações genéticas que impedem o desenvolvimento das células T. Assim sendo, a 
disfunção grave de células T impede uma resposta humoral efetiva, visto que as células 
B necessitam de sinalização por parte das células T para desenvolver anticorpos. Tendo 
por base a análise de dados de um estudo combinado prospectivo do programa de 
rastreio neonatal nos Estados Unidos da América, estimou-se que a incidência de SCID é 
1 em 58.000 recém-nascidos. O diagnóstico precoce de SCID antes de qualquer sintoma 
clínico ou ocorrência de complicações graves está provado estar associado a melhores 
taxas de sobrevivência após o tratamento com transplante de células percursoras 
hematopoiéticas, que é o tratamento recomendado. 
Esta revisão bibliográfica analisa as vantagens e desvantagens da implementação 
do rastreio de SCID em todos os programas de rastreio neonatal. 
O motor de busca utilizado para a pesquisa de artigos foi o PubMed. 
Neste trabalho, uma apresentação das características da SCID, os métodos de 
rastreio disponíveis para detectar esta doença e o custo-benefício inerente ao rastreio 
são apresentados, para clarificar todos os componentes que necessitam de ser 
considerados para a adição de uma nova doença a um programa de rastreio neonatal. 
Concluindo, o método de rastreio para a SCID que quantifica os círculos de 
excisão do receptor das células T usando uma técnica de reação em cadeia de 
polimerase de transcrição reversa para quantificação em tempo real tem um bom custo-
benefício, tem uma sensibilidade e uma especificidade de quase 100% e permite detectar 
a doença num estádio precoce, quando ainda tem bom prognóstico. Este método já foi 
implementado em alguns países e tem demonstrado bons resultados. 
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Introduction 
The concept of “primary immunodeficiency” comprises a group of genetic diseases 
that result from inherited defects of the immune system(1). Combined immunodeficiency 
syndromes are a heterogeneous group of diseases that result from a disturbance in the 
development and function of both T and B cells, from the cellular and humoral immunity(2, 
3). Furthermore, some of them are termed “severe” because the course of this disease 
leads to early death from opportunistic infections, normally in the first year of life (if not 
diagnosed and treated)(4-7). 
Severe combined immunodeficiency (SCID) is an important health problem. Based 
on the records from a combined prospective data analysed from the neonatal screening 
program in the United States of America (USA), the incidence of SCID is approximately 1 
in 58.000 infants(8). The only exception from the data that is available is from the Navajo 
Nation, whose incidence is 1 in 3.500 infants(9, 10). However, this increased incidence is 
related to a mutation in the DCLRE1C gene that causes SCID, which is frequent in this 
population(9). 
SCID is the most severe form of primary immunodeficiency(11). This syndrome is 
caused by genetic mutations that block the development of T cells (4). However, these 
mutations can also affect the B cells lineage. In addition to that, serious T cell dysfunction 
precludes effective humoral immunity, as B cells require signalization from T cells to 
generate antibodies(4). Moreover, SCID can affect the natural killer (NK) cells(12). 
In order to correct this disease in newborn babies, there must be an early detection 
and these patients must be referenced to specialized centres. Nowadays, the standard 
treatment for patients with SCID is: 
• Hematopoietic stem cell transplantation (HSCT) HLA-identical or HLA-
haploidentical(13-28); 
• Enzyme replacement therapy is another option of treatment in some cases of 
adenosine deaminase deficiency-SCID (ADA-SCID)(4); 
• Gene therapy, which is an alternative for some forms of SCID (ADA-SCID and 
X-linked SCID – common gama-chain deficiency)(29). 
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Methods 
The research was performed on PubMed, using the following formula of MeSH 
words: ("severe combined immunodeficiency"[MeSH Terms] OR ("severe"[All Fields] AND 
"combined"[All Fields] AND "immunodeficiency"[All Fields]) OR "severe combined 
immunodeficiency"[All Fields]) AND ("neonatal screening"[MeSH Terms] OR 
("neonatal"[All Fields] AND "screening"[All Fields]) OR "neonatal screening"[All Fields]. 
Inclusion criteria included studies, review articles or case reports; written in 
English, Portuguese, Italian or Spanish; published between 1st of January of 2003 and 31th 
of December of 2017; with full text available; whose articles were related to the analysis of 
the severe combined immunodeficiency and its neonatal screenings already available. 
Some opinion articles were excluded. Some articles older than the mentioned timeframe 
were included because a historic reference was made about neonatal screening and its 
development. 
 
Results 
A total of 149 articles were analysed from which 45 articles that met the inclusion 
criteria were selected.  
Based on the selected articles, the relevant information was collected for the 
review and organised according to the type of study performed as to compose the body of 
the review.  
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Neonatal screening 
The neonatal screening of newborn infants started in 1963 according to the paper 
presented by Robert Guthrie and Ada Susi, for the screening of phenylketonuria(30). They 
proposed the use of dried blood spots collected from a heel stick, blotted on a filter paper 
after 2 to 5 days from the date of birth to be analysed by specialized laboratories(30). This 
was the first step to create a newborn screening. A few years later, in 1968, after a 
conference organised by the World Health Organization (WHO), Wilson and Jungner 
proposed 10 criteria to have in consideration when a new disorder to be proposed for 
population screening(31). 
The criteria that Wilson and Jungner proposed initially were: 
1. The condition sought should be an important health problem. 
2. There should be an accepted treatment for patients with recognized diseases. 
3. Facilities for diagnosis an treatment should be available. 
4. There should be a recognizable latent or early symptomatic stage. 
5. There should be a suitable test or examination. 
6. The test should be acceptable to the population. 
7. The natural history of the condition, including development from latent to declared 
disease, should be adequately understood. 
8. There should be an agreed policy on whom to treat. 
9. The cost of case finding (including diagnosis) should be economically balanced in 
relation to possible expenditure on medical healthcare as a whole. 
10. Case finding should be a continuing process and not a ‘once and for all’ project. 
In 2008, Andermann, Blancquaert, Beauchamp and Dery proposed a review of the 
criteria because there was a need to adapt them (32). So, the criteria proposed were (32-
34): 
1. There should be scientific evidence of screening programme effectiveness and the 
benefits of screening should be shown to outweigh the harm.   
2. The test may be multiplexed or overlaid onto an existing structure or system.   
3. The ‘diagnostic odyssey’ for the patient/family may be reduced or eliminated.   
4. Adverse outcome(s) are rare with a false-positive test.   
5. Treatment costs may be covered by third parties (either private or public).  
6. Testing may be declined by parents/guardians.   
7. Adequate pretesting information or counselling is available to parents/guardians.   
8. Screening in the newborn period is critical for  prompt diagnosis and treatment.  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9. Public health infrastructure is in place to support all phases of the testing, diagnosis 
and  interventions.   
10. If carriers are identified, genetic counselling is  provided.   
11. Treatment risks and the impact of a false-positive test are explained to 
parents/guardians. 
12. The limitations of screening and risks of a false-negative test are explained to 
parents/guardians. 
Based on these criteria, we are proposing that the severe combined 
immunodeficiency should be included in most of the Europeans neonatal screenings. 
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Severe Combined Immunodeficiency 
SCID can be classified according to the immunophenotype (for example: T-B+NK+ - 
absence of T cells and presence of B and NK cells; T-B-NK+ - absence of T and B cells 
and presence of NK cells)(4, 35). In fact, T cells are always absent in every type of SCID. 
However, nowadays, the appropriate classification of SCID takes in consideration 
the specific molecular defect that is causing the immunodeficiency. So far, according to 
the International Union of Immunological Societies (IUIS) there have been discovered 16 
genes that can cause SCID and each one of them has different clinical features that can 
help when the physician is investigating the case(5, 36). In Table I, is presented the 
classification of the mutation according to the pathogenic mechanism and the genotype 
and Table II shows the clinical features associated with the genetic defect of some SCID 
(5, 36). 
Table I. Pathogenetic mechanism of SCID  
Pathogenetic mechanism Gene mutated 
Immuno-
phenotype 
Inheritance 
Defective survival of haematopoietic 
precursors  
AK2 T-B-NK- AR 
Toxic metabolite accumulation  ADA 
PNP  
T-B-NK- 
T-B+NK- 
AR 
AR 
Cytokine signaling anomalies  IL2RG 
 JAK3 
 IL-7RA 
T-B+NK- 
T-B+NK- 
T-B+NK+ 
XL 
AR 
AR 
V(D)J recombination and TCR 
abnormalities  
RAG1/RAG2, 
DCLRE1C, PRKDC, 
NHEJ1, LIG4 
T-B-NK+ AR 
TCR abnormalities  PTPRC 
CD3D, CD3E, CD247 
CORO1A 
T-B+NK+ 
T-B+NK+ 
T-B-NK+ 
AR 
AR 
AR 
Thymic abnormalities  FOXN1 T-B+NK+ AR 
AR: autosomal recessive transmission; XL: X-linked transmission 
Adapted from Cirillo et al.(5) 
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Table II. Clinical phenotypes associated with each known genetic defect 
Gene 
defect 
Phenotype Pathogenic mechanism Reference 
AK2 Ommen syndrome Peripheral expansion of 
oligoclonal T lymphocytes 
 
(37) 
IL2RG (γc) 
JAK3 
Hodgkin like features, invagination 
and hemophagocytic 
lymphohistiocytosis  
Selective CD4+ T lymphopenia  
Not clear; maternal graft 
versus host disease  
Hypomorphic mutation 
associated with somatic 
chimerism  
(38-40) 
RAG Granulomatous lesions, EBV-
related lymphoma, Idiopatic CD4+ T 
lymphopenia with extensive 
chickenpox  
Hypomorphic mutations  (41) 
CORO1A EBV B cell lymphoproliferation  Not clear; null and 
hypomorphic mutations  of 
CORO1A in mice 
are associated with defects in 
T cell survival and migration  
(42) 
FOXN1 Eczematous rash, erythroderma, 
severe diarrhea and alopecia  
Residual T cell development 
sustained by rudimentary 
thymus or extrathymic 
lymphoid sites  
(43) 
EBV: Epstein-Barr virus 
Adapted from Cirillo et al.(5) 
In fact, regardless of the immunological phenotype, infants with SCID present 
similar features as: early-onset and recurrent severe infections, chronic diarrhea and 
growth impairment(44, 45). Hypermetabolism is more common in SCID patients with 
growth impairment and may contribute to its development(46). As a matter of fact, all 
affected infants will have a fatal outcome unless specific measurements to contain the 
situation are taken, such as: strict isolation and prophylactic antibiotics(44).  
To conclude, early diagnosis of SCID before any clinical symptom or serious 
complication is proven to improve the survival rates after the HSCT(29, 47). The results of 
these studies show that children who have done the HSCT at the age of 3,5 months or 
younger and without a history of infection have 90-94% of survival rate, in 5 years; 
children that have undergone HSCT after 3,5 months of life have 69-90% of survival rate, 
in 5 years, if they have no history of infection or the infection was resolved by the time of 
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transplantation; children older than 3,5 months and with an active infection during HSCT 
have 50% of survival rate, in 5 years(29, 47). 
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Screening 
The importance of screening for SCID is that if the diagnose is not done before the 
asymptomatic stage, the prognosis is dismal. This way, the screening for SCID can 
reduce the morbidity and mortality associated with it(48). As presented previously, SCID 
fulfils the requirements, proposed by WHO, to be a part of a population-based neonatal 
screening(49). 
Effectively, there are already numerous studies showing that the inclusion of SCID 
in newborn screening programs fills in the requirements by WHO: is asymptomatic at 
birth; treatment is more effective as soon as precocious as it is possible, preventing the 
rate of infections and other complications; it helps in genetic counselling and pre-birth 
diagnose; and, it allows to know the prevalence and the spectrum of SCID(25, 49-52). 
In 2007, Puck verified that children with family history of SCID were being 
diagnosed more precociously (the average age of diagnosis was 2 months) and lead to a 
survival rate of 100% when compared to the group of children that was diagnosed just 
after the appearance of the first symptoms related to SCID(53). In this study, from the 32 
children that were diagnosed with SCID after the appearance of the first symptoms: 8 died 
before they received any treatment; from the 24 that received appropriate treatment only 
14 survived, presenting a 44% rate of survival amongst the children with SCID and that do 
not have family history(53). 
In 2013, Kwan et al. presented their results after including SCID in the newborn 
screening program in California State(54). In this study, the authors verified that SCID and 
other diseases with a number of lymphocytes lower than 1500 T cells/μL had a higher 
prevalence than half of the diseases that were part of the newborn screening program in 
USA(54). 
After the results presented by Puck and the proposal for the introduction of SCID in 
the newborn screening in some states from the USA, there were several pilot studies 
worldwide. In Europe, more specifically, pilot studies were done in the United Kingdom, 
France, Spain, Sweden, Netherlands, old Serbia-Montenegro and Germany(55-61). 
Worthy of notice is the fact that in all these studies, they have reached a common 
conclusion: the sooner the diagnosis of SCID, better the prognosis after applying the 
appropriate treatment and fewer were the complications after the treatment. 
In 2018, the screening of SCID was already included in the newborn screening 
program in all states of the USA, in the Netherlands, in Norway, in the region of Catalonia, 
in Israel and in Taiwan (Jeffrey Modell Foundation, http://www.info4pi.org).(8, 62) 
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Available Screening Tests 
Since the scientific community thought of including SCID in the newborn screening, 
there have already been presented many screening tests: absolute count of 
lymphocytes(25, 63-65); detection of proteins from T cells CD3 and leukocytes markers 
CD45 based on the ligation with antibodies(66); an immunoassay with interleukin-7(53, 
67); genetic mapping(68); and, the quantification of T-cell receptor excision circles 
(TREC)(50). 
The proposal of using the absolute lymphocyte count considers that typical forms 
of SCID present lymphopenia due to reduced number of T cells(63-65). In these studies, it 
was proposed that a value of lymphocytes inferior of 2500 cells/μl would be suspicious of 
SCID(63, 65). After that, a flow cytometry would be performed in order to determine the 
presence of T, B and NK cells, the quantity of T cells receptors and the response of the T 
cells to mitogen or antigen stimulations to confirm the diagnosis(65). Despite the good 
results from this test, this technique has low sensibility, so it misdiagnoses patients with 
high levels of B cells and possibly NK cells or patients with residual, autoreactive (e.g. 
Omen syndrome) or alloreactive (transplacentally acquired maternal cells) T 
lymphocytes(65). To conclude, this test is not useful to be used as a screening test for 
SCID, specially, because of the overlap between healthy infants and infants with 
SCID(44). 
In 2010, Janik et al. developed a study to evaluate the applicability of a multiple 
immunoassay (CD345) as a method of detection of SCID in newborns(66). In this assay, 
they used dried blood samples (DBS)(66). CD3 was utilized as a marker for T cells and 
CD45 as a marker for lymphocytes in general(66). The results were positive, however due 
to the possibility that not all newborns with SCID present lymphopenia, this test could not 
be used as screening, it could just be used as a complementary test to screen SCID(66). 
McGee, Stiehm, Cowan, Krogstad and McCabe, in 2005, studied the use of 
interleukin-7 (IL-7) as a screening test for SCID, using dried blood samples(67). The IL-7 
is a cytokine involved in the development of the T cells. In this study, the sensibility of the 
IL-7 was estimated to be 85% for this screening method, so this method was cleared as a 
possibility for a population-based screening for SCID(67). 
Another possibility that was studied as a screening method for SCID was genetic 
mapping using the Guthrie cards. This technique is used in some screenings such as the 
one for cystic fibrosis, but in terms of SCID, not all the DNA sequence variants are thought 
to have been discovered(68). Despite that, Lebet et al., in 2008, published a study where 
a technique of resequencing capable of detecting known and unknown SCID variants 
(developed by Puck and Warrington) was being used (69). This technique was able to 
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identify 90% of all known mutations as well as previously unknown ones in prospective 
SCID cases(69). To conclude, this method would leave a lot of false negative cases and 
that is why it is not a good screening method(68). 
In 2005, Chan and Puck described the utility of DBS (also known as Guthrie cards) 
for the detection of TREC by quantity polymerase-chain reaction (PCR) techniques as a 
screening method (50). The TREC molecules are fragments of DNA excised from the T-
cell receptor (TCR) gene during the development of mature lymphocytes inside the 
thymus(44, 68, 70, 71). As all infants with SCID have reduced T lymphocyte development, 
they have low numbers of T cells derived from the thymus and consequently very low or 
absent TREC values, compared to the normal infants(70, 72). As TREC are stable in the 
peripheral circulation, the isolation of DNA by PCR from DBS can be used to quantify 
TREC in a population-based screening(11, 68, 72). The validity of this test has been 
demonstrated following the introduction of SCID screening in the USA in 2008(54, 73, 74). 
The TREC quantification using reverse transcription for real-time quantitative 
polymerase chain reaction (RTqPCR) is the one that has been showing better results 
using peripheral blood(44, 50, 75). Nevertheless, despite the fact that this method 
requires a blood sample from the infants, the manual extraction of the DNA, the use of the 
RTqPCR technic, genetic control, the analysis of the data and, initially, the difficulties to 
implement this test as a screening method(49, 66, 76); the scientific community has 
accepted it very well as it presents a lot of advantages: the possibility of using the Guthrie 
cards (already used for the newborn screening of other diseases), the low cost, the 
elevated efficiency and sensibility to detect the cases of SCID, even in newborn infants 
that have high levels of maternal T cells in peripheral blood(68, 77). In addition to typical 
SCID, Omenn Syndrome and non-SCID immunodeficiencies associated with marked T 
cells lymphopenia may be detected by the TREC screening test including: partial 
DiGeorge syndrome, CHARGE (coloboma, heart anomalies, choanal atresia, retardation 
of growth and development, and genital and ear anomalies) syndrome, cartilage–hair 
hypoplasia (CHH) and ataxia telangiectasia(77-82). On the other hand, the TREC method 
has one potential limitation: inability to detect some cases of SCID due to combined 
immunodeficiencies associated with gene defects that affect the development later than 
the T-cell receptor recombination or associated with impaired T-cell signalling, survival or 
proliferation(79, 82-84). Examples of this are the adenosine deaminase (ADA) with 
delayed onset disease, ZAP-70 deficiency and major histocompatibility complex (MHC) 
class II deficiency (79, 82-84). 
Nowadays, in order to detect primary immunodeficiencies, it is possible to add to 
the TREC essay the analysis of the kappa-deleting recombination excision circles 
(KREC), which is a sensitive marker of B cells development, increasing the rate of 
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immunodeficiencies diagnosis that are associated with low numbers of B lymphocytes 
(such as: late onset ADA deficiency, Nijmegen-breakage syndrome, X-linked 
agammaglobulinemia (XLA) and purine nucleoside phosphorylase (PNP) deficiency)(85-
87). To conclude, the combined assay (TREC and KREC) has been suggested to be 
included in routine screening for primary immunodeficiency (11, 12, 86, 88). 
In practice, the TREC method measures the quantity of TREC available in the 
blood samples and, also, β-actin, as an internal control for DNA amplification. In cases 
which β-actin measure is too low (Adams et al. proposed a β-actin cut-off of 35 copies/μL) 
re-tests must be run to validate the results, independently of the values of TREC in that 
sample(56). According to a recent systematic review done by van der Speck, Groenwold, 
van der Burg and van Montfrans, a TREC cut-off of 25 copies/μL may be an appropriate 
initial value for implementation of routine newborn screening for SCID(7). In addition to 
this, when analysing the results and the cut-off used in this test, it must be considered that 
premature infants, infants with trisomy 21 and infants whose mother has taken 
immunosuppressive agents during pregnancy have lower TREC values compared to term 
and healthy infants, without needing to have any of the diseases that cause low TREC 
values (7, 54, 60, 70, 89). To conclude, the possible results from the TREC essay are 
four: presumptive cases with TREC copies/μL below the cut-off, whose cases need an 
immediate confirmatory test (flow cytometry is recommended); borderline cases with 
TREC copies/μL at the cut-off level, for which a second screening test should be 
performed; normal results with TREC copies/μL higher than the cut-off; and, inconclusive 
results with an unsatisfactory level of β-actin cut-off lower than the cut-off(90). 
This method already allowed to detect more than 100 cases of SCID and, 
according to all published studies, the screening programmes that use TREC as a 
measure for identifying the cases of typical and atypical SCID have never left any case 
undetected or lately detected(7, 8, 79). 
According to Chan et al., the sensibility of the TREC test using the RTqPCR 
technic is estimated to be 99,5%(91); although, there have been no known missed 
cases(91). Kwan et al., estimated this same test to have a sensibility of 99,97%(54). 
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In Portugal 
In 2016, the Portuguese Group for the Primary Immunodeficiencies presented a 
national and multicentre retrospective analysis for all know cases of SCID in Portugal 
since the year 2000(92). This group of researchers concluded that the incidence of SCID 
is 1 in 48.775 newborn; the average date for the first clinical manifestations is at 4,1 
months; the average date between the first clinical manifestations and the diagnose is 2,5 
months, which makes the average age of diagnosis 6,6 months; and, the mortality is 
60%(92). 
The Portuguese Group for Primary Immunodeficiencies presented this data in 
order to compare with the statistics from countries that have already included SCID 
screening in their neonatal programs(92). It was concluded that the incidence, despite 
being superior than most of the published studies, it is under-estimated and that the 
diagnosis is done so late that 37% of the infants die before the HSCT(92). These 
conclusions reinforce the need for the implementation of the screening for SCID in most of 
the neonatal screening programs all over the World. 
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Cost-Effectiveness 
In spite of the efficiency of the tests, the inclusion of a disease in a population-
based screening program must be analysed in terms of cost-effectiveness. 
In 2016, Ding et al. proposed a model to estimate the cost and the benefits of the 
newborn screening program using the TREC method to detect SCID(90). For that, the 
authors modified the model structure from a cost-benefit analysis model developed during 
2011-2012 by the Washington Newborn Screening program and used the data available 
from previous cost-benefit reviews and, also, the cohort from the Washington Newborn 
Screening program(90). 
The incremental costs of adding SCID to a screening program (with the laboratory 
test and administrative costs), cost of diagnostic test (flow cytometry), costs of the 
treatment for early-diagnosed or late-diagnosed SCID infants and costs of deaths are 
specified in Table 3(90). The costs of individual sample collection and transport are not 
affected by this screening, as this test uses the Guthrie cards already used for other 
screenings(90). Ding et al. adjusted these values to 2012 USA dollars using the 
healthcare component of the Personal Consumption Expenditures Price Indexes(90). 
Table 3. Model variables and ranges 
Variables Base-
case 
Range/Alternative References 
Birth prevalence of SCID 1/58.000 1/46.000-1/80.000 (8) 
Proportion of SCID cases detected without 
the screening 
0,203  (25, 93) 
Sensitivity of the TREC method 99,50% 99,00%-100,00% (8, 91) 
Specificity of the TREC method 99,97% 99,92%-99,98% (54, 94) 
Survival rate 
For early-identified SCID (pretreatment) 
For early-identified SCID (posttreatment) 
For late-identified SCID (pretreatment) 
For late-identified SCID (posttreatment) 
 
94% 
94% 
78% 
69% 
  
(8) 
(8, 25, 95) 
(91, 93) 
(47, 72) 
Costs of screening and diagnosis 
Lab tests for TREC assay sample 
Short-term follow-up per positive case 
Flow cytometry per case 
 
$4,04 
$50,00 
$250,0 
 
$3,00-$6,00 
 
(90) 
(90) 
(90, 91) 
Costs of treatment 
Average cost per infant with SCID who 
die before definitive treatment 
Average cost per infant with ADA-SCID 
who do not undergo early HSCT 
Average cost for infants with SCID who 
 
$300.000 
 
$450.000 
 
 
 
 
 
$200.000-$750.000 
 
 
 
(90) 
 
(90) 
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receive HSCT as first-line therapy 
Per early-idenitifed baby 
Per late-identified baby 
 
$100.000 
$450.000 
 
$80.000-$120.000 
$300-000-$1.200.000 
 
(72, 91, 96) 
(72, 90, 96) 
Adapted from Ding et al. (90)  
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Conclusion 
SCID is a primary immunodeficiency that brings enormous implications to the 
quality of life from the affected infants and their life expectancy. As referred, if the 
diagnosis of the syndrome is not done before the first symptoms, life expectancy 
diminishes considerably when compared to patients that are diagnosed in the first three 
months of life. In addition to this, the TREC test using the RTqPCR technic has already 
been proven to be a very sensible and specific test, without excluding any case of SCID. 
That is why this test is already used in some countries as a population-based screening. 
Furthermore, the TREC test has proven to have good cost-effectiveness. 
To conclude, this review brings up the important facts related to the screening of 
SCID, supporting the idea that screening SCID using the TREC technique in the newborn 
programs should be included worldwide, as it improves the quality of life, expectancy of 
life and diminish the expenses in health. 
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